Premium
Associations of high sensitivity C ‐reactive protein levels with the prevalence of asymptomatic intracranial arterial stenosis
Author(s) -
Wang J.,
Liu Y.,
Zhang L.,
Li N.,
Wang C.,
Gao X.,
Zhou Y.,
Wang A.,
Wu S.,
Zhao X.
Publication year - 2014
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/ene.12342
Subject(s) - asymptomatic , medicine , odds ratio , c reactive protein , confidence interval , stenosis , logistic regression , cardiology , cohort , gastroenterology , inflammation
Background and purpose High sensitivity C ‐reactive protein (hs‐ CRP ), an inflammatory biomarker, has been demonstrated to contribute to the process of atherosclerosis and artery stenosis. The aim of this study was to evaluate whether hs‐ CRP level is associated with asymptomatic intracranial artery stenosis ( ICAS ). Methods A random sample of 5440 participants aged 40 years or older (40.1% women) were enrolled in the A symptomatic P olyvascular A bnormalities C ommunity study in 2010–2011. Information on the potential risk factors for ICAS was collected and the presence of ICAS was assessed by transcranial Doppler in 5309 participants. Participants were stratified into three groups according to hs‐ CRP levels. A multivariate logistic regression was used to examine the association between hs‐ CRP levels and asymptomatic ICAS . Results The prevalence of asymptomatic ICAS was 13.2% in this cohort. The median of hs‐ CRP levels was positively associated with the increasing numbers of ICAS s. After adjusting for possible risk factors, hs‐ CRP ≥ 3 mg/l remained significantly associated with asymptomatic ICAS (odds ratio 1.28, 95% confidence interval 1.02–1.61). Conclusions In this large community‐based study, subjects with higher hs‐ CRP levels showed a mild increase in the prevalence of asymptomatic ICAS , independent of traditional vascular risk factors. hs‐ CRP is an independent predictor of asymptomatic ICAS and intracranial atherosclerotic burden.